Results from a Clinical Study of the BioScanIR System Conducted at the Leipzig Heart Center to Be Presented at the Mayo Clinic Vascular Symposium.

EAST SETAUKET, N.Y. -- Non-contact, Non-Radiologic Functional Imaging Tool Demonstrates Quantitative Blood Flow Verification of Coronary Bypass Grafts

OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT) today announced that the results of a clinical study conducted at Herzzentrum Leipzig, University of Leipzig (The Heart Center Leipzig) in Leipzig, Germany, a world renowned cardiovascular center, will be presented at the 3rd Annual Mayo Clinic Vascular Symposium, "Advances and Controversies in the Medical, Endovascular and Surgical Treatment of Vascular Disease." The study, entitled "Modelling of temperature mapping for quantitative dynamic infrared coronary angiography for intraoperative graft patency control," is authored by a leading research team in the field that includes Jens Garbade, M.D., Marcus Hollenstein, Ph.D., Cris Ullmann, Ph.D., Prof. Volkmar Falk, M.D., Jan Fritz Gummert, Ph.D. and Prof. Friedrich Wilhelm Mohr, M.D. The aim of the study was to use the BioScanIR(R) System to develop a heat-transfer model for quantitative flow estimation in a pre-clinical animal study and then compare these results to clinical results both in arrested and beating heart coronary artery bypass grafting (CABG) in humans. The researchers concluded that the method "enables the estimation of actual graft flow using DIR imaging. Despite only small temperature gradients in off-pump surgery, the method can be applied for non-invasive no-touch graft flow estimation in beating heart surgery."

The results will be presented by Mihai Dimancescu, MD, an internationally recognized neurosurgeon and OmniCorder's V.P. of Medical Affairs, on September 27th at the Mayo Clinic Gonda Vascular Center in Rochester, Minnesota.

Mark A. Fauci, CEO and President of OmniCorder Technologies, Inc., stated, "The results of this study are very important as they demonstrate the BioScanIR(R)'s ability to be used as a means of quality control during the surgery while the chest is still open and corrective measures can more easily be applied. While heart bypass surgery (CABG) is the most frequently performed surgical procedure, there are no widely- accepted, safe, non-contact methods to check the quality of the new graft prior to closing the patient's chest. These results represent an important milestone for quantitative assessment of bypass grafts during CABG surgery. It is also a very important milestone for OmniCorder. With over a half-million of these procedures performed every year in the United States and Europe, this application represents a very significant opportunity for us to improve surgical outcomes and reduce healthcare delivery costs."

About Leipzig Heart Center:

Herzzentrum Leipzig has a team of approximately 900 highly qualified and motivated staff who work under the direction of doctors and scientists of international reknown. The hospital specializes in the comprehensive diagnosis, therapy and surgical treatment of all diseases affecting the cardiovascular system.

About The Mayo Clinic Gonda Vascular Center:

The Mayo Clinic Gonda Vascular Center in Rochester is devoted to providing state-of-the-art diagnosis and treatment services in a compassionate environment for patients with peripheral vascular diseases. These diseases include arterial occlusive disease (atherosclerosis or hardening of the arteries), venous obstruction and clotting, venous incompetence/insufficiency, cerebrovascular disease including carotid bruits, aneurysms, thoracic outlet syndrome, vasospastic disorders including Raynaud's, lymphedema, vascular ulcerations, vasculitis, and other vascular disorders.

The BioScanIR(R) System:

The Company's BioScanIR(R) System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR(R) System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.

About OmniCorder Technologies, Inc.:

OmniCorder Technologies Inc., headquartered in East Setauket, New York, is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.

OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.